Chemotherapeutic Efficacy of Rutin in Triple Negative Breast Cancer

Abstract

Cancer is a complex group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. It causes millions of deaths each year and remaining a significant global health concern for both men and women. Effective treatment strategies are crucial for improving patient outcomes in breast cancer, particularly in the case of triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Chemotherapy, like paclitaxel and docetaxel, is the standard treatment for TNBC due to the lack of targeted therapies for this subtype. Paclitaxel (PTX) is a widely used chemotherapeutic medication that is particularly effective against lung, ovarian, and other cancers; nevertheless, its clinical use is limited due to its multi-organ toxicity. As a result, the current study aims to improve treatment efficacy and reduce PTX-induced toxicity through the concurrent use of the natural polyphenolic substance Rutin. Rutin hydrate (purity > 94%) and paclitaxel were utilized in in vitro studies with 4T1 and MDA MB-231 cell lines. In the proliferation assay, cells were treated with rutin and paclitaxel at varying concentrations. Cytochrome-c release and cell cycle analysis were conducted, and flow cytometry assessed apoptosis. According to the findings of this investigation, rutin in combination with PTX considerably (P<0.05) lowers the growth and proliferation of breast cancer cell lines in vitro. Furthermore, flow cytometry research revealed that combining rutin with PTX triggered GO/Gl cell cycle arrest and apoptosis in a breast cancer cell line. Furthermore, after co-administration of rutin and PTX, mitochondrial depolarization increased significantly (P<0.05). Thus, the current study convincingly established rutin’s sensitizing activity and suggests it could be a potential adjuvant in cancer chemotherapy.